Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-10-27

Clinical Trial Update: Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial comparing T2750 to Vismed for moderate to severe dry eye disease, with results reported in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • T2750
  • Vismed

Snippet

Sponsor: Laboratoires Thea | Conditions: Dry Eye Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2014-10-27